PSTX

Poseida Therapeutics, Inc.

2.75 USD
-0.01 (-0.36%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Poseida Therapeutics, Inc. stock is down -13.79% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 37.21% of the previous 50 June’s closed higher than May. 100% of analysts rate it a buy.

About Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC)